The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).
Julie E. Bauman
Research Funding - Bristol-Myers Squibb; Genentech; Lilly
William E. Gooding
No relevant relationships to disclose
David Andrew Clump
No relevant relationships to disclose
Seungwon Kim
No relevant relationships to disclose
Brian J Karlovits
No relevant relationships to disclose
Dwight Earl Heron
No relevant relationships to disclose
Umamaheswar Duvvuri
Honoraria - Novartis
James Ohr
No relevant relationships to disclose
Karen Holeva
No relevant relationships to disclose
Robert L. Ferris
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb
Research Funding - Amgen; Bristol-Myers Squibb